Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case -88% Improvement Relative Risk Case (b) 8% HCQ for COVID-19  Shahrin et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 336 patients in Bangladesh (March - July 2020) More cases with HCQ (not stat. sig., p=0.088) c19hcq.org Shahrin et al., Life, December 2022 Favors HCQ Favors control

Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Providers with Its Potential Side-Effects

Shahrin et al., Life, doi:10.3390/life12122047
Dec 2022  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 230 low risk healthcare workers taking HCQ prophylaxis, and 106 that declined, showing higher cases without statistical significance. No case severity information is provided. The point estimate favored HCQ when excluding the first 14 days and including participants that worked for at least 16 days. Authors note a significant dose response relationship.
risk of case, 87.8% higher, RR 1.88, p = 0.09, treatment 43 of 230 (18.7%), control 11 of 106 (10.4%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of case, 8.0% lower, OR 0.92, p = 0.89, adjusted per study, excluding the first 14 days and including participants that worked for at least 16 days, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shahrin et al., 7 Dec 2022, retrospective, Bangladesh, peer-reviewed, median age 34.0, 11 authors, study period 31 March, 2020 - 12 July, 2020.
Contact: lubabashahrin@icddrb.org (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Providers with Its Potential Side-Effects
Lubaba Shahrin, Mustafa Mahfuz, Md. Waliur Rahman, Md. Rezaul Hossain, Afsana Mim Khandaker, Md Md. Ashraful Alam, Din M M F Osmany, Md Md. Munirul Islam, Mohammod Jobayer Chisti, Chaudhury Meshkat Ahmed, Tahmeed Ahmed
Life, doi:10.3390/life12122047
Considering that it has been more than 24 months since SARS-CoV-2 emerged, it is crucial to identify measures that prevent and control pathogen transmission in workplace settings. Our aim was to report results of a hospital-based program that delivered hydroxychloroquine (HCQ) tablets as COVID-19 prophylaxis to the frontline healthcare workers (HCW)s who cared for COVID-19 patients and to evaluate the efficacy of HCQ. Setting and participants: Quasi-experimental, controlled, single-center study. The included participants were doctors, nurses, health workers, cleaning staff, and non-healthcare supportive staff. The main outcome was contracting COVID-19 anytime during the period of taking the prophylaxis, confirmed by RT-PCR. A total of 336 participants, without any clinical evidence of COVID-19 and without any known contact with family members, were included in the trial; 230 were assigned to HCQ and 106 declined to take any drug. Results: Among the participants, 43 (18.7%) in the HCQ group and 11 (10.4%) participants in the control group developed COVID-19. For the evaluation of side effects, we evaluated 12-lead ECGs of both groups at the baseline and after 4 weeks to monitor QTc interval. A total of 91% (198 of 217) participants in the prophylaxis group and 92% (11 of 12) in the control group had a QTc < 45o msec, which is within normal limits. Conclusions: Although the number of symptomatic infections in health personnel was lower in the control group, the difference was not statistically significant. However, in the absence of any effective pre-exposure prophylaxis medicine for COVID-19, practicing proper infection prevention and control (IPC) and vaccination is the only way forward.
There are a few limitations of our study. The first limitation was that the participants did not have any baseline RT-PCR tests performed to confirm their COVID-19 status before beginning the prophylaxis. The second limitation was that the investigator had no control over the participants regarding practicing IPC properly at the workplace or elsewhere. Finally, as the trial was un-blinded, the control group might have taken extra precautions in practicing IPC measures than the prophylaxis group. Finally, as no pharmacological agents seems to be proved protective as a prophylaxis for COVID-19, we have to reinforce the infection prevention practice and vaccination [32, 33] , which are still considered as the best practice for the prevention of transmission of SARS-CoV-2. Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/life12122047/s1, Supplementary Table S1 : Decision on baseline ECG; Supplementary Table S2 : Tisdale risk factor assessment score; and Supplementary Table S3 : CONSORT checklist. Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Data Availability Statement: All data related with this research can be made available under institutional policy. For data access, requests should be made to aahmed@icddrb.org, Head, Research Administration, icddr, b. Conflicts of Interest: The authors declare no conflict of interest.
References
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2016638
Chahla, Ruiz, Ortega, Morales, Barreiro et al., A randomized trial-intensive treatment based in Ivermectin and Iota-Carrageenan as pre-exposure prophylaxis for COVID-19 in healthcare agents, medRxiv
Cohen, Hydroxychloroquine for the prevention of COVID-19-Searching for evidence, Mass Med. Soc
Consortium, Repurposed antiviral drugs for COVID-19-Interim WHO SOLIDARITY trial results, N. Engl. J. Med, doi:10.1056/NEJMoa2023184
Director, General's Opening Remarks at the Media Briefing on COVID-19-11
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis, doi:10.1016/S1473-3099(20)30120-1
Elgazzar, Hany, Youssef, Hafez, Moussa et al., Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic, Europe PMC, doi:10.21203/rs.3.rs-100956/v3
Fang, Benson, Del Rio, Edwards, Fowler et al., COVID-19-Lessons learned and questions remaining, Clin. Infect. Dis, doi:10.1093/cid/ciaa1654
Hernandez, Roman, Pasupuleti, Barboza, White, Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: A living systematic review, Ann. Intern. Med, doi:10.7326/M20-2496
Iacobucci, COVID-19: Doctors sound alarm over hospital transmissions, Br. Med. J. Publ. Group, doi:10.1136/bmj.m2013
Infante, Ricordi, Alejandro, Caprio, Fabbri, Hydroxychloroquine in the COVID-19 pandemic era: In pursuit of a rational use for prophylaxis of SARS-CoV-2 infection, Expert Rev. Anti-Infect. Ther, doi:10.1080/14787210.2020.1799785
Ingram, Downey, Roe, Chen, Archibald et al., COVID-19 prevention and control measures in workplace settings: A rapid review and meta-analysis, Int. J. Environ. Res. Public Health, doi:10.3390/ijerph18157847
Jones, Rivett, Sparkes, Forrest, Sridhar et al., Effective control of SARS-CoV-2 transmission between healthcare workers during a period of diminished community prevalence of COVID-19, Elife, doi:10.7554/eLife.59391
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.105924
Lu, Zhao, Li, Niu, Yang et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding, Lancet, doi:10.1016/S0140-6736(20)30251-8
Meyerowitz, Vannier, Friesen, Schoenfeld, Gelfand et al., Rethinking the role of hydroxychloroquine in the treatment of COVID-19, FASEB J
Miller, Novel Coronavirus COVID-19 (2019-nCoV) Data Repository, Bull.-Assoc. Can. Map Libr. Arch, doi:10.15353/acmla.n164.1730
Niriella, Ediriweera, De, Silva, Premarathne et al., Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: Study protocol for a randomized, controlled trial, Trials, doi:10.1186/s13063-020-04659-7
Perrone, Schilling, Callery, Ashley, Chambers et al., Good participatory practice for coronavirus disease 2019 (COVID-19) research: The case of a COVID-19 prevention study, Wellcome Open Res, doi:10.12688/wellcomeopenres.16880.2
Ramireddy, Chugh, Reinier, Ebinger, Park et al., Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: Implications for QT interval monitoring, J. Am. Heart Assoc, doi:10.1161/JAHA.120.017144
Revollo, Tebe, Peñafiel, Blanco, Perez-Alvarez et al., Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers, J. Antimicrob. Chemother, doi:10.1093/jac/dkaa477
Rojas-Serrano, Portillo-Vásquez, Vázquez-Pérez, Ramírez-Venegas, Pérez-Kawabe et al., Hydroxychloroquine for Prophylaxis of COVID-19 in Health Workers: A Randomized Clinical Trial, PLoS ONE
Shah, Das, Jain, Misra, Negi, A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19), Int. J. Rheum. Dis, doi:10.1111/1756-185X.13842
Sherzad, Tu, Liu, Azimee, Arash et al., The Situation and Preventive Measures Related to COVID-19 Infection for Medical Staff, J. Pharm. Res. Int, doi:10.9734/jpri/2021/v33i43A32477
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol. J, doi:10.1186/1743-422X-2-69
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wecot, Medicines UoE; World Health Organization. The Selection and Use of Essential Medicines: Report of the WHO Expert Committee
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis, doi:10.1093/cid/ciaa237
Zhou, Dai, Tong, COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J. Antimicrob. Chemother, doi:10.1093/jac/dkaa114
Zhu, Zhang, Wang, Li, Yang et al., China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, N. Engl. J. Med, doi:10.1056/NEJMoa2001017
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit